16 completed, 4 recruiting, 3 active not recruiting, 2 enrolling by invitation. 5 Phase 2, 5 Phase 3, 4 Not applicable, 4 Phase 1, 1 Early Phase 1.
Follow Inclusion Body Myositis: new trials by email Literature Review of Inclusion Body Myositis trials Research Report on Inclusion Body Myositis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body Myositis IBM, Inclusion Body Myositis | Recruiting | Johns Hopkins University | 30 | 2026-11-01 | 2026-10-28 | |
| IBM Dietary Surveillance Study Whole-Body Dual-Energy X-ray Absorptiometry, Anthropometry, Capillary Blood Sampling - Inclusion Body Myositis | Not yet recruiting | Manchester Metropolitan University | 47 | 2026-04-30 | 2026-04-17 | |
| Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease Whole-body Electrical Muscle Stimulation Exercise - Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis | Not applicable | Recruiting | University of Missouri-Columbia | 50 | 2026-03-10 | 2026-03-17 |
| The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period. Assistive gait devices combined with physiotherapy - Inclusion Body Myositis, Myotonic Dystrophy 1 | Not applicable | Enrolling by invitation | LMU Klinikum | 30 | 2025-09-01 | 2025-07-18 |
| MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS) No intervention - qualitative and mixed methods investigations - IBM, IIM | Recruiting | Myositis International Health & Research Collaborative Alliance Foundation | 700 | 2025-06-25 | 2026-01-28 | |
| Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders FBIndex - Inclusion Body Myositis, Myotonic Dystrophy | Enrolling by invitation | LMU Klinikum | 108 | 2024-09-09 | 2025-09-10 | |
| Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time PAMSys pendant PAMSys wrist sensors - Inclusion Body Myositis | Active not recruiting | University of Kansas Medical Center | 20 | 2023-11-16 | 2026-06-29 | |
| The Risk of Falls Index for Patients With Neuromuscular Disorders The risk of falls - Inclusion Body Myositis, Myotonic Dystrophy | Completed | LMU Klinikum | 30 | 2023-09-01 | 2024-09-19 | |
| A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis ABC008 - Inclusion Body Myositis | Phase 2 / Phase 3 | Completed | Abcuro, Inc. | 272 | 2023-02-28 | 2026-10-01 |
| Cell Therapy for IBM by Muscle Injection of ADSVF ADSVF - Inclusion Body Myositis | Phase 1 | Unknown | Assistance Publique - Hôpitaux de Paris | 32 | 2023-02-01 | 2023-03-22 |
| Phase III Trial of Sirolimus in IBM Sirolimus, Placebo - Inclusion Body Myositis | Phase 3 | Active not recruiting | University of Kansas Medical Center | 140 | 2022-07-01 | 2026-01-14 |
| Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease Beck depression inventory fast screen (Questionnaire), Brief Pain Inventory (BPI) (Questionnaire), German Pain Inventory (Questionnaire) - Pompe Disease (Late-onset), Inclusion Body Myositis | Unknown | LMU Klinikum | 95 | 2022-03-31 | 2023-10-10 | |
| Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells Adipose Derived Regenerative Cells - Inclusion Body Myositis | Not applicable | Completed | University of Kansas Medical Center | 9 | 2022-03-10 | 2025-12-17 |
| Sporadic Inclusion Body Myositis Natural History Study Sporadic Inclusion Body Myositis, Inclusion Body Myositis | Active not recruiting | University of California, Irvine | 150 | 2021-10-11 | 2026-05-27 | |
| A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM) ABC008 - Inclusion Body Myositis | Phase 1 | Completed | Abcuro, Inc. | 19 | 2021-05-25 | 2025-02-20 |
| Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis Phenylbutyrate Oral Tablet - Inclusion Body Myositis, Sporadic Inclusion Body Myositis | Phase 1 | Completed | University of Kansas Medical Center | 10 | 2020-08-20 | 2024-09-19 |
| Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial Arimoclomol - Inclusion Body Myositis | Phase 3 | Terminated | ZevraDenmark | 121 | 2019-05-20 | 2023-09-15 |
| Establishing Muscle Impedance Parameters With Electrical Impedance Myography electrical impedance myography (EIM) - IBM, Inclusion Body Myositis | Completed | Yale University | 31 | 2018-06-19 | 2020-08-11 | |
| Study of Pioglitazone in Sporadic Inclusion Body Myositis Pioglitazone - Myositis, Inclusion Body Myositis | Phase 1 | Completed | Johns Hopkins University | 19 | 2018-05-22 | 2021-01-12 |
Showing 20 of 30. Sign in to see all of them.
Myositis, Inclusion Body (30) · Myositis (8) · Dermatomyositis (5) · Neuromuscular Diseases (5) · Polymyositis (5) · Glycogen Storage Disease Type II (4) · Muscular Dystrophy, Facioscapulohumeral (4) · Amyotrophic Lateral Sclerosis (3) · Lambert-Eaton Myasthenic Syndrome (3) · Muscular Atrophy, Spinal (3) · Muscular Diseases (3) · Myasthenia Gravis (3) · Myotonic Dystrophy (3) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (3) · Friedreich Ataxia (2)
Musculoskeletal Diseases (29) · Nervous System Diseases (28) · Muscular Diseases (27) · Neuromuscular Diseases (25) · Myositis (22) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (6) · Metabolic Diseases (6) · Neurodegenerative Diseases (6) · Nutritional and Metabolic Diseases (6) · Pathological Conditions, Signs and Symptoms (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Autoimmune Diseases (5) · Autoimmune Diseases of the Nervous System (5)
arimoclomol (3) · Blood Specimen Collection (2) · Anthropometry (1) · Calorimetry, Indirect (1) · Etanercept (1) · Interleukin 1 Receptor Antagonist Protein (1) · Magnetic Resonance Spectroscopy (1) · Oxygen (1) · Phenylbutyrates (1) · Physical Therapy Modalities (1) · Pioglitazone (1) · Sirolimus (1) · Vital Signs (1) · Walk Test (1) · gamma-Globulins (1)
LMU Klinikum (4) · University of Kansas Medical Center (4) · Abcuro, Inc. (2) · Johns Hopkins University (2) · National Institute of Environmental Health Sciences (NIEHS) (2) · ZevraDenmark (2) · Assistance Publique - Hôpitaux de Paris (1) · Centre Hospitalier Universitaire de Nice (1) · Institut de Myologie, France (1) · Jay C. Buckey Jr. (1) · Karolinska Institutet (1) · Manchester Metropolitan University (1) · Myositis International Health & Research Collaborative Alliance Foundation (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Phoenix Neurological Associates, LTD (1)
United States (19) · Germany (5) · United Kingdom (5) · France (4) · Australia (3) · Belgium (1) · Canada (1) · Netherlands (1) · Sweden (1)
Mazen Dimachkie (2) · Mazen Dimachkie, MD (2) · Abdullah Z AlQahtani, MD MPH (1) · Adam I Schiffenbauer, M.D. (1) · Bhaskar Roy, MBBS (1) · David D Saperstein, MD (1) · Duaa Jabari, MD (1) · Glenn Lopate, MD (1) · Jay Buckey (1) · Jemima Albayda, MD (1) · Lesley Ann Saketkoo, MD, MPH (1) · Lisa G Rider, M.D. (1) · Mazen M Dimachkie (1) · Michael Hanna (1) · Michael Hanna, MD (1)
PMID 16267188, PMID 16849828, PMID 16900450, PMID 22003934, PMID 28168524, PMID 37739573, PMID 38059274, PMID 38960586, PMID 40018746, PMID 41832158
R01AR078340 (1)